NMN and NR Employer Coverage, ICHRA, HSA/FSA: How to Cut Your Out-of-Pocket Cost in 2026

What NMN and NR Actually Are, and Why Coverage Is Complicated

NMN and NR are NAD+ precursors. Both molecules raise intracellular nicotinamide adenine dinucleotide (NAD+) levels, a coenzyme tied to mitochondrial function, DNA repair, and sirtuin signaling. Because NAD+ declines with age, starting around the third decade of life, supplementing its precursors has attracted significant research interest.

The coverage complication is regulatory. NMN and NR are currently sold as dietary supplements, not approved drugs. The FDA's Division of Dietary Supplement Programs has not cleared any NMN or NR product as a new drug application. That single fact determines almost every insurance and reimbursement rule downstream.

The FDA Classification Problem

In November 2022, FDA's Office of Dietary Supplement Programs sent a warning letter clarifying that beta-NMN had been the subject of substantial clinical investigations before being marketed as a supplement, raising questions about its continued supplement status. That regulatory ambiguity has not been fully resolved as of early 2026, which means some compounding pharmacies continue to compound NMN as a prescription ingredient while others have paused. The FDA's current dietary supplement guidance remains the controlling document for retailers.

Why This Matters for Employer Plans

Group health plans governed by ERISA are required to cover only services that meet the plan's definition of a "covered benefit." Because NMN and NR carry no approved indication, no CPT code, and no National Drug Code classification as a prescription drug in most plan formularies, a standard employer group health plan will deny a claim for either supplement outright. The path to reimbursement runs through different vehicles entirely, described below.

Human clinical data does support biological activity. A 2022 randomized, double-blind, placebo-controlled trial (N=30) published in npj Aging found that oral NMN 250 mg/day for 12 weeks significantly elevated whole-blood NAD+ concentrations compared with placebo (P<0.001). This kind of evidence builds a clinician's rationale for prescribing, but it does not create an insurance coverage obligation.

HSA and FSA Eligibility for NMN/NR

HSA and FSA accounts can reimburse NMN or NR expenses, but only under a specific condition: the purchase must qualify as a "medical care" expense under IRS Section 213(d). Vitamins and supplements purchased for general health are explicitly excluded by IRS Publication 502. The key is a clinician's prescription tied to a diagnosed condition.

The Prescription Requirement

A licensed physician, nurse practitioner, or other prescriber must document a specific medical indication, such as mitochondrial dysfunction, a confirmed NAD+ deficiency workup, or a condition where NAD+ repletion has a plausible therapeutic rationale. The prescription itself does not guarantee HSA/FSA eligibility, but it is the foundation of any defensible reimbursement claim.

The IRS publication 502 guidance on medical expenses states that a prescribed drug is deductible when it is "prescribed by a physician for a specific individual." Compounded NMN prepared by a licensed 503A pharmacy and dispensed with a patient-specific prescription fits that description more cleanly than an over-the-counter bottle.

Compounded NMN as a Prescription Medical Expense

Several telehealth platforms now prescribe compounded NMN as a patient-specific formulation through 503A compounding pharmacies, which operate under FDA's compounding pharmacy framework. This route converts NMN from a retail supplement into a prescription compounded drug, making the expense more defensible for HSA/FSA reimbursement.

A 2023 randomized trial (N=80) published in GeroScience demonstrated that 900 mg/day oral NMN for 60 days improved muscle insulin sensitivity in postmenopausal women with prediabetes, providing a concrete clinical rationale that a prescriber could document.

Practical HSA/FSA Filing Steps

1. Obtain a letter of medical necessity (LMN) or a prescription from your clinician specifying the compound, dose, and diagnosis.
2. Purchase through a licensed pharmacy or telehealth pharmacy partner.
3. Submit the pharmacy receipt and LMN to your HSA or FSA administrator.
4. Keep documentation for three years in case of IRS audit.

Some HSA administrators auto-approve prescription receipts. Others require manual review. Contact your plan administrator before assuming approval.

ICHRA Reimbursement for NMN and NR

An Individual Coverage HRA (ICHRA) is an employer-funded arrangement that reimburses employees for qualifying individual health insurance premiums and, depending on plan design, other Section 213(d) medical expenses. The IRS finalized ICHRA rules in 26 CFR Parts 1, 54, and 602, allowing employers to offer tax-free reimbursements without a traditional group plan.

What ICHRA Can and Cannot Cover

ICHRA can reimburse Section 213(d) medical expenses beyond premiums if the employer designs the plan that way. The same prescription/medical necessity rule applies: NMN or NR reimbursed under an ICHRA must qualify as a medical expense, not a general wellness purchase.

Employers can structure their ICHRA to explicitly include compounded prescription costs. A 2026-compliant ICHRA plan document should list "compounded medications prescribed by a licensed clinician" as a covered expense category. Without that language, the claims administrator may reject the request.

Employer Steps to Add NMN Coverage to an ICHRA

1. Amend the ICHRA plan document to include compounded prescription drugs as a reimbursable category.
2. Require employees to submit a prescription receipt from a licensed pharmacy.
3. Confirm the third-party administrator (TPA) can process compounded Rx receipts.
4. Set an annual reimbursement sublimit if desired, such as $1,200/year for compounded medications, to control cost exposure.

The IRS Notice 2023-37 clarified that HRA plan sponsors retain flexibility in defining eligible expense categories, as long as those categories do not exceed Section 213(d) boundaries.

ICHRA vs. Excepted Benefit HRA (EBHRA)

An EBHRA provides up to $2,100 per year (2026 indexed amount) for excepted benefits. It cannot reimburse NMN or NR because the excepted benefit definition does not include compounded prescription supplements. ICHRA is the correct vehicle, not EBHRA, for this reimbursement pathway.

Employer Wellness Stipends and Taxable Fringe Benefits

Many employers now offer a wellness stipend, a fixed annual dollar amount employees can spend on health-related purchases including supplements, fitness equipment, and telehealth memberships. Unlike HSA/FSA or ICHRA dollars, wellness stipend reimbursements are taxable income to the employee under IRS Section 132 unless the specific expense qualifies as a Section 213(d) medical expense.

Structuring a Wellness Stipend Correctly

If an employer reimburses NMN under a general wellness stipend without a prescription, that reimbursement is included in the employee's W-2 gross income. The employee still saves money compared to paying retail, but there is no tax exemption. Common annual wellness stipend amounts range from $500 to $2,500 per employee, and many technology and pharmaceutical employers have added NAD+ precursors to their approved wellness purchase lists.

Combining Stipend with HSA

An employee cannot double-dip: if a wellness stipend reimburses an NMN purchase, that same purchase cannot also be claimed from an HSA. The expense can only be reimbursed once. Plan accordingly by using the stipend for non-prescription supplement purchases and the HSA for the prescription-grade compounded version if both benefits are available.

The Prescription vs. Supplement Decision: A Clinical Framework

The choice between purchasing OTC NMN as a supplement versus obtaining a compounded Rx version affects both your reimbursement options and the quality of the product you receive. Here is how the decision tree works in practice.

OTC Supplement Route

• No prescription needed.
• Not reimbursable through HSA, FSA, or ICHRA without a clinician's order.
• Wide price variation: third-party testing by ConsumerLab has identified potency discrepancies of up to 40% in commercial NMN products.
• No pharmacy oversight or sterility guarantee.

The NIH Office of Dietary Supplements does not currently maintain a fact sheet on NMN, reflecting the unsettled evidence base for OTC dosing guidance.

Compounded Prescription Route

• Requires a telehealth or in-person prescriber visit.
• Eligible for HSA, FSA, or ICHRA reimbursement with proper documentation.
• Prepared under USP <795> or USP <797> standards by a licensed 503A pharmacy.
• Typically costs $80, $150/month dispensed, versus $40, $100/month for retail OTC.
• The price premium is offset if you are reimbursed pre-tax.

A 2021 Phase 1 dose-escalation trial (N=10) published in NPJ Aging confirmed that single oral doses of NMN up to 500 mg were safe and well-tolerated in healthy Japanese men, and elevated plasma NMN and NAD+ metabolite levels in a dose-dependent manner. This pharmacokinetic data underpins the prescriber rationale for compounding at defined doses.

Pre-Tax Savings Calculator Example

Assume an employee in the 22% federal bracket, 5% state bracket, and 7.65% FICA rate:

• Monthly compounded NMN cost: $120.
• Annual cost: $1,440.
• Pre-tax savings via HSA/FSA: approximately $498/year (34.65% effective rate).
• Net annual cost: approximately $942.

That calculation does not include any employer ICHRA contribution, which could reduce the net cost further toward zero.

Evidence Base: What Human Trials Show in 2026

The clinical literature on NMN and NR has grown substantially since 2020. This section summarizes the trials most relevant to a prescriber drafting a letter of medical necessity.

NMN Human Trials

The Yoshino et al. 2021 trial published in Science (N=25 postmenopausal women with prediabetes or obesity) found that 250 mg/day oral NMN for 10 weeks improved skeletal muscle insulin signaling and gene expression compared with placebo, though weight and fasting glucose did not differ significantly between groups.

The 2022 Liao et al. Trial (N=30) referenced above demonstrated NAD+ elevation at 250 mg/day, the lowest dose tested, suggesting even conservative prescribing produces measurable biological effect.

A 2023 RCT by Yi et al. (N=66, aged 40 to 65) published in GeroScience showed 900 mg/day NMN for 60 days improved grip strength and reduced fatigue scores compared with placebo in middle-aged adults, with no serious adverse events reported.

NR Human Trials

Trammell et al.'s foundational 2016 pharmacokinetics paper published in Nature Communications (N=12) demonstrated that a single 1,000 mg oral dose of NR significantly raised blood NAD+ and its metabolites within 6 hours.

Martens et al. 2018, published in Nature Communications (N=120), showed that NR 1,000 mg/day for 6 weeks reduced arterial stiffness and systolic blood pressure in adults with mild hypertension. The mean systolic reduction was 5.5 mmHg (P<0.01), a clinically meaningful finding for a prescriber treating cardiovascular risk.

Dollerup et al. 2018, published in Cell Metabolism (N=40, obese men), found NR 1,000 mg/day for 12 weeks safe and well-tolerated with no significant metabolic changes in that particular population, illustrating that outcomes are population-dependent.

What Prescribers Typically Document

For a defensible letter of medical necessity, a clinician typically notes: age-related NAD+ decline, a specific metabolic or mitochondrial diagnosis, prior workup including fasting insulin or HOMA-IR, and a therapeutic goal with a defined reassessment timeframe of 90 to 180 days. Without that structure, HSA administrators may reject the claim.

Navigating the 2026 Employer Benefits Field

Benefits administrators and HR professionals handling employee requests for NMN coverage should be aware of two 2026-specific developments.

IRS Position on Supplement Reimbursement

The IRS has not issued a ruling specific to NMN or NR. Its general position, detailed in Publication 502, is that supplements are not deductible unless prescribed for a specific disease. That standard has not changed. What has changed is the number of telehealth platforms offering prescribed compounded NMN, which creates a larger pool of employees arriving with legitimate prescriptions.

ERISA Preemption and Self-Funded Plans

Self-funded employer plans governed by ERISA have more flexibility than fully insured plans. A self-funded employer can amend its summary plan description (SPD) to cover compounded NMN as a prescription benefit. The Department of Labor's ERISA compliance guidance requires the SPD to clearly describe covered benefits, so any amendment must be distributed to employees within 210 days after the plan year in which the change is adopted.

Some forward-thinking employers in the longevity medicine space have added NAD+ precursors to their prescription drug rider. This is still rare but growing, particularly among biotech and life sciences companies whose workforces include employees already taking NMN or NR on physician recommendation.

How to Get NMN or NR Cheaper: Summary of Cost-Reduction Strategies

Retail NMN pricing ranges from roughly $0.80 to $3.00 per 500 mg dose depending on brand and quantity. Here are the highest-impact ways to reduce that cost in 2026.

Strategy 1: Use Pre-Tax Dollars

Obtain a prescription. Use HSA or FSA funds to pay. At a combined marginal rate of 30%, a $1,200/year NMN habit costs $840 after tax. That is the single largest discount available and requires no coupon or manufacturer program.

Strategy 2: Ask Your Employer About ICHRA or Wellness Stipend

If your employer offers an ICHRA or wellness stipend, confirm whether compounded prescription costs or supplement purchases are listed as eligible. A brief email to HR referencing IRS Notice 2019-45, which expanded HSA-eligible preventive care services, may prompt a plan amendment conversation.

Strategy 3: Buy in Bulk from Third-Party Tested Brands

For employees without HSA/FSA access or a prescription, buying a 3- or 6-month supply from a brand with current NSF International or USP Verified certification reduces per-dose cost by 15 to 30% versus monthly purchases. Always verify the certificate of analysis is current; NMN degrades with heat and humidity.

Strategy 4: Telehealth Subscription Bundles

Several telehealth platforms bundle the prescriber visit, lab work (baseline NAD+ metabolomics or fasting metabolic panel), and compounded NMN dispensing into a monthly membership. These bundles typically run $150, $250/month all-in, compared to $200, $400/month for a la carte services. The entire bundle may be HSA-eligible if the telehealth visit itself qualifies under IRS Notice 2021-15, which extended HSA-compatible telehealth coverage rules.

Strategy 5: Clinical Trial Enrollment

Multiple NMN and NR trials listed on ClinicalTrials.gov are actively recruiting as of 2026. Enrollment provides free study drug and monitoring. Search for open Phase 2 trials in your age bracket and condition profile. Eligibility typically requires age 40 or older, no active cancer, and no concurrent use of other NAD+ precursors.